213 related articles for article (PubMed ID: 33314803)
1. Comparison of inflammation-based prognostic scores as predictors of survival outcomes in patients with germ cell tumors.
Yoshinaga K; Sadahira T; Maruyama Y; Mitsui Y; Iwata T; Wada K; Araki M; Watanabe T; Nasu Y
Investig Clin Urol; 2021 Jan; 62(1):47-55. PubMed ID: 33314803
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the predictive value among inflammation-based scoring systems for bleomycin pulmonary toxicity in patients with germ cell tumors.
Maruyama Y; Sadahira T; Araki M; Mitsui Y; Wada K; Edamura K; Kobayashi Y; Watanabe M; Watanabe T; Nasu Y
Int J Urol; 2019 Aug; 26(8):813-819. PubMed ID: 31115106
[TBL] [Abstract][Full Text] [Related]
3. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
[TBL] [Abstract][Full Text] [Related]
4. Novel immunological and nutritional-based prognostic index for gastric cancer.
Sun KY; Xu JB; Chen SL; Yuan YJ; Wu H; Peng JJ; Chen CQ; Guo P; Hao YT; He YL
World J Gastroenterol; 2015 May; 21(19):5961-71. PubMed ID: 26019461
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of prognostic inflammation-based and/or nutritional markers in patients with stage III gastric cancer.
Toyokawa T; Muguruma K; Yoshii M; Tamura T; Sakurai K; Kubo N; Tanaka H; Lee S; Yashiro M; Ohira M
BMC Cancer; 2020 Jun; 20(1):517. PubMed ID: 32493247
[TBL] [Abstract][Full Text] [Related]
6. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
He CB; Lin XJ
PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy.
Li QQ; Lu ZH; Yang L; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li J; Li Y; Shen L
Asian Pac J Cancer Prev; 2014; 15(2):945-50. PubMed ID: 24568523
[TBL] [Abstract][Full Text] [Related]
8. A Novel Inflammation-Based Stage (I Stage) Predicts Overall Survival of Patients with Nasopharyngeal Carcinoma.
Li JP; Chen SL; Liu XM; He X; Xing S; Liu YJ; Lin YH; Liu WL
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27854304
[TBL] [Abstract][Full Text] [Related]
9. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
Ogul A; Kidi MM; Buyuksimsek M
J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment C-reactive protein/albumin ratio is associated with poor survival in patients with stage IB-IIA cervical cancer.
Zhang W; Liu K; Ye B; Liang W; Ren Y
Cancer Med; 2018 Jan; 7(1):105-113. PubMed ID: 29193777
[TBL] [Abstract][Full Text] [Related]
11. The Relationship Between Preoperative Systemic Immune Inflammation Index and Prognostic Nutritional Index and the Prognosis of Patients With Alveolar Hydatid Disease.
Ren B; Chen X; Lei P; Hou L; Wang H; Zhou Y; Ren L; Fan H; Wang Z; Yuan J
Front Immunol; 2021; 12():691364. PubMed ID: 34248983
[TBL] [Abstract][Full Text] [Related]
12. Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer: Glasgow Prognostic Score Is the Most Reliable Parameter.
Yamada S; Fujii T; Yabusaki N; Murotani K; Iwata N; Kanda M; Tanaka C; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Medicine (Baltimore); 2016 May; 95(18):e3582. PubMed ID: 27149487
[TBL] [Abstract][Full Text] [Related]
13. Preoperative prognostic nutritional index and systemic immune-inflammation index predict survival outcomes in osteosarcoma: A comparison between young and elderly patients.
Ma C; Yu R; Li J; Guo J; Xu J; Wang X; Liu P
J Surg Oncol; 2022 Mar; 125(4):754-765. PubMed ID: 34811745
[TBL] [Abstract][Full Text] [Related]
14. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer.
Liu Y; Chen S; Zheng C; Ding M; Zhang L; Wang L; Xie M; Zhou J
BMC Cancer; 2017 Apr; 17(1):285. PubMed ID: 28431566
[TBL] [Abstract][Full Text] [Related]
16. The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma.
Chen C; Sun P; Dai QS; Weng HW; Li HP; Ye S
PLoS One; 2014; 9(11):e112581. PubMed ID: 25393117
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment low prognostic nutritional index and low albumin-globulin ratio are predictive for overall survival in nasopharyngeal cancer.
Gundog M; Basaran H
Eur Arch Otorhinolaryngol; 2019 Nov; 276(11):3221-3230. PubMed ID: 31401760
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
19. The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma.
Zhang H; Shang X; Ren P; Gong L; Ahmed A; Ma Z; Ma R; Wu X; Xiao X; Jiang H; Tang P; Yu Z
J Cell Physiol; 2019 Feb; 234(2):1794-1802. PubMed ID: 30070689
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
Cafferty FH; White JD; Shamash J; Hennig I; Stenning SP; Huddart RA;
Eur J Cancer; 2020 Mar; 127():139-149. PubMed ID: 32007714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
